CorMedix Inc
NASDAQ:CRMD
CorMedix Inc
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
Record Quarter: CorMedix posted its strongest quarter ever, with record revenue of $104.3 million, net income of $108.6 million, and adjusted EBITDA of $71.8 million, mainly fueled by DefenCath adoption and the Melinta acquisition.
Guidance Raised: The company increased full-year revenue guidance to $390–410 million and raised 2025 adjusted EBITDA expectations to $220–240 million.
Melinta Acquisition: CorMedix closed the Melinta Therapeutics deal, accelerating integration and expecting to capture $30 million of synergies by year-end.
Strategic Investments: CorMedix made a minority investment in Talphera, gaining a right-of-first negotiation pending Phase III results in 2026.
DefenCath Momentum: Strong demand for DefenCath, with faster-than-expected ramp at large dialysis organizations and continued cohort expansion; minimal inventory stocking noted.
Key Pipeline Milestones: Top-line results from the RESPECT study for Rezzayo and expansion of DefenCath into TPN patients expected as major catalysts in 2026–2027.
Cash Position: Ended Q3 with $55.7 million in cash, expecting to end the year near $100 million, backed by operational cash flow.
